Dexiang Chen

Summary

Affiliation: Program for Appropriate Technology in Health
Country: USA

Publications

  1. doi request reprint Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method
    D Chen
    PATH, Seattle, WA 98121, USA
    Vaccine 28:5093-9. 2010
  2. doi request reprint Desirable attributes of vaccines for deployment in low-resource settings
    Dexiang Chen
    PATH, Seattle, Washington 98121, USA
    J Pharm Sci 102:29-33. 2013
  3. doi request reprint Opportunities and challenges of developing thermostable vaccines
    Dexiang Chen
    PATH, Seattle, WA 98107, USA
    Expert Rev Vaccines 8:547-57. 2009
  4. doi request reprint Spray drying and vaccine stabilization
    David McAdams
    PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
    Expert Rev Vaccines 11:1211-9. 2012
  5. ncbi request reprint Characterization of the freeze sensitivity of a hepatitis B vaccine
    Dexiang Chen
    PATH, Seattle, Washington, USA
    Hum Vaccin 5:26-32. 2009
  6. doi request reprint Vaccine stabilization: research, commercialization, and potential impact
    Debra Kristensen
    PATH, Seattle, WA, United States
    Vaccine 29:7122-4. 2011
  7. doi request reprint Strategies to advance vaccine technologies for resource-poor settings
    Debra Kristensen
    PATH, Seattle, WA 98121, USA
    Vaccine 31:B157-62. 2013
  8. ncbi request reprint An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model
    Melissa S Burger
    PowderJect Vaccines, Inc, Seattle, WA, USA
    J Allergy Clin Immunol 114:1301-8. 2004

Collaborators

  • Debra Kristensen
  • David McAdams
  • Melissa S Burger
  • Qili Chu
  • Lendon G Payne
  • Cindy L Zuleger
  • Xiaoyan Gao

Detail Information

Publications8

  1. doi request reprint Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method
    D Chen
    PATH, Seattle, WA 98121, USA
    Vaccine 28:5093-9. 2010
    ..This study demonstrates the feasibility of producing thermostable vaccines with advanced processing and formulation technologies...
  2. doi request reprint Desirable attributes of vaccines for deployment in low-resource settings
    Dexiang Chen
    PATH, Seattle, Washington 98121, USA
    J Pharm Sci 102:29-33. 2013
    ....
  3. doi request reprint Opportunities and challenges of developing thermostable vaccines
    Dexiang Chen
    PATH, Seattle, WA 98107, USA
    Expert Rev Vaccines 8:547-57. 2009
    ..The challenges associated with the implementation of these novel formulations are discussed, as well as the potential benefits and opportunities of taking vaccines out of the cold chain...
  4. doi request reprint Spray drying and vaccine stabilization
    David McAdams
    PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
    Expert Rev Vaccines 11:1211-9. 2012
    ..This article reviews the status of spray-drying technology and discusses barriers and opportunities for its future application to vaccines...
  5. ncbi request reprint Characterization of the freeze sensitivity of a hepatitis B vaccine
    Dexiang Chen
    PATH, Seattle, Washington, USA
    Hum Vaccin 5:26-32. 2009
    ....
  6. doi request reprint Vaccine stabilization: research, commercialization, and potential impact
    Debra Kristensen
    PATH, Seattle, WA, United States
    Vaccine 29:7122-4. 2011
    ..Public sector agencies can incentivize vaccine developers to prioritize stabilization efforts through advocacy and by implementing policies that increase demand for thermostable vaccines...
  7. doi request reprint Strategies to advance vaccine technologies for resource-poor settings
    Debra Kristensen
    PATH, Seattle, WA 98121, USA
    Vaccine 31:B157-62. 2013
    ....
  8. ncbi request reprint An antigen-independent but not antigen-specific T(H)1 response provides protection in the murine airway inflammation model
    Melissa S Burger
    PowderJect Vaccines, Inc, Seattle, WA, USA
    J Allergy Clin Immunol 114:1301-8. 2004
    ..Synthetic oligodeoxynucleotides containing unmethylated CG dinucleotides (CpG) are strong T(H)1 adjuvants and are being investigated for allergy immunotherapy...